. Author manuscript; available in PMC: 2013 Aug 6.

Published in final edited form as: Breast Cancer Res Treat. 2010 Jul 30;128(1):79–84. doi: 10.1007/s10549-010-1080-z

Table 1.

KRAS 3′UTR SNP genotype frequencies among indexes from BRCA1, BRCA2, and non-BRCA1/BRCA2 families

Population	Genotype	Frequency	OR	95% CI	P value
Controls	GG+TG	138/797 (17.3%)	1.00
	TT	659/797 (82.7%)
BRCA1 carriers	GG+TG	63/268 (23.5%)	1.47	1.05–2.06	0.025^*
	TT	205/268 (76.5%)
BRCA2 carriers	GG+TG	12/89 (13.5%)	0.74	0.39–1.40	0.36
	TT	77/89 (86.5%)
Non-BRCA1/BRCA2 carriers	GG+TG	108/685 (15.8%)	0.89	0.68–1.18	0.42
	TT	577/685 (84.2%)
ER-positive	GG+TG	63/356 (17.7%)	1.03	0.74–1.43	0.87
	TT	293/356 (82.3%)
ER-negative	GG+TG	18/127 (14.2%)	0.79	0.46–1.34	0.38
	TT	109/127 (85.8%)

Differences in KRAS-variant allele frequencies between cases and controls were tested for significance by a χ²-test. Case–control odds ratios and their confidence intervals were calculated using Woolf approximations

After adjustment for multiple testing (Bonferroni correction for three tests) the P-value between BRCA1 carriers and controls was not statistically significant anymore (P = 0.073)